Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
OI
MCID: ORT004
MIFTS: 69

Orthostatic Intolerance (OI)

Categories: Cardiovascular diseases, Genetic diseases, Mental diseases, Neuronal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Orthostatic Intolerance

About this section

MalaCards integrated aliases for Orthostatic Intolerance:

Name: Orthostatic Intolerance 58 77 76 38 30 13 6 17
Mitral Valve Prolapse 12 77 38 30 56 6 44 45 15 64
Neurocirculatory Asthenia 58 12 45 15 74
Mitral Valve Prolapse Syndrome 58 74
Irritable Heart 58 74
Familial Orthostatic Tachycardia Due to Norepinephrine Transporter Deficiency 60
Postural Orthostatic Tachycardia Syndrome Due to Net Deficiency 60
Cardiovascular Malfunction Arising from Mental Factors 12
Orthostatic Intolerance Due to Net Deficiency 60
Mitral Valve Prolapse, Familial, X-Linked 74
Myxomatous Mitral Valve Prolapse 12
Systolic Click-Murmur Syndrome 12
Pots Due to Net Deficiency 60
Intolerance, Orthostatic 41
Cardiovascular Neurosis 12
Mitral Leaflet Syndrome 12
Floppy Mitral Valve 12
Da Costa's Syndrome 12
Krishaber's Disease 12
Barlow's Syndrome 12
Soldiers Heart 58
Oi 76

Characteristics:

Orphanet epidemiological data:

60
postural orthostatic tachycardia syndrome due to net deficiency
Inheritance: Autosomal dominant;

HPO:

33
orthostatic intolerance:
Inheritance autosomal dominant inheritance


Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases
Anatomical: Neuronal diseases Mental diseases Cardiovascular diseases
See all MalaCards categories (disease lists)
ICD10: 35
Orphanet: 60  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:11569 DOID:988
OMIM 58 604715
ICD9CM 36 306.2
NCIt 51 C50655
ICD10 via Orphanet 35 I95.1
Orphanet 60 ORPHA443236
SNOMED-CT via HPO 70 263681008
Sources

Summaries for Orthostatic Intolerance

About this section
MedlinePlus : 44 Mitral valve prolapse (MVP) occurs when one of your heart's valves doesn't work properly. The flaps of the valve are "floppy" and don't close tightly. Most people who have the condition are born with it. It also tends to run in families. Most of the time, MVP doesn't cause any problems. Rarely, blood can leak the wrong way through the floppy valve. This can cause Palpitations (feelings that your heart is skipping a beat, fluttering, or beating too hard or too fast) Shortness of breath Cough Fatigue, dizziness, or anxiety Migraine headaches Chest discomfort Most people who have mitral valve prolapse (MVP) don't need treatment because they don't have symptoms and complications. If you need treatment for MVP, medicines can help relieve symptoms or prevent complications. Very few people will need surgery to repair or replace the mitral valve. MVP puts you at risk for infective endocarditis, a kind of heart infection. To prevent it, doctors used to prescribe antibiotics before dental work or certain surgeries. Now, only people at high risk of endocarditis need the antibiotics. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Orthostatic Intolerance, also known as mitral valve prolapse, is related to postural orthostatic tachycardia syndrome and arteries, anomalies of, and has symptoms including angina pectoris, edema and chest pain. An important gene associated with Orthostatic Intolerance is SLC6A2 (Solute Carrier Family 6 Member 2), and among its related pathways/superpathways are Peptide ligand-binding receptors and NFAT and Cardiac Hypertrophy. The drugs Midodrine and Droxidopa have been mentioned in the context of this disorder. Affiliated tissues include heart, brain and testes, and related phenotypes are orthostatic tachycardia and cardiovascular system

Disease Ontology : 12 A mitral valve disease where one or both of the cusps of the mitral valve bulge or collapse backward in the left atrium during systole.

UniProtKB/Swiss-Prot : 76 Orthostatic intolerance: Syndrome characterized by lightheadedness, fatigue, altered mentation and syncope. It is associated with postural tachycardia. Plasma norepinephrine concentration is abnormally high.

PubMed Health : 64 About mitral valve prolapse: Mitral (MI-tral) valve prolapse (MVP) is a condition in which the heart's mitral valve doesn't work well. The flaps of the valve are "floppy" and don't close tightly. These flaps normally help seal or open the valve.Much of the time, MVP doesn't cause any problems. Rarely, blood can leak the wrong way through the floppy valve. This can lead to palpitations, shortness of breath, chest pain, and other symptoms. (Palpitations are feelings that your heart is skipping a beat, fluttering, or beating too hard or too fast.)

Wikipedia : 77 Mitral valve prolapse (MVP; a.k.a. floppy mitral valve syndrome, systolic click murmur syndrome or... more...

Description from OMIM: 604715
Sources

Related Diseases for Orthostatic Intolerance

About this section

Diseases in the Orthostatic Intolerance family:

Chronic Orthostatic Intolerance

Diseases related to Orthostatic Intolerance via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 262)
# Related Disease Score Top Affiliating Genes
1 postural orthostatic tachycardia syndrome 33.8 AGTR1 FBN1 SLC6A2
2 arteries, anomalies of 31.1 AGTR1 EDN1 NOS3
3 coronary artery anomaly 31.0 ADRB1 ADRB2 AGTR1 EDN1 NOS3
4 hypermobile ehlers-danlos syndrome 31.0 FBN1 PLOD1
5 mitral valve disease 30.5 AGTR1 FBN1 NOS3
6 congestive heart failure 30.3 ADRB1 ADRB2 AGTR1 EDN1
7 heart disease 30.3 ADRB1 AGTR1 ECE1 EDN1 FLNA NOS3
8 dilated cardiomyopathy 30.2 ADRA2C ADRB1 ADRB2 AGTR1 EDN1 NOS3
9 myocardial infarction 30.1 ADRA2B ADRB1 ADRB2 AGTR1 EDN1 NOS3
10 aortic coarctation 30.0 ADRB1 ADRB2 AGTR1 EDN1 FBN1 NOS3
11 acute myocardial infarction 29.9 ADRB1 AGTR1 EDN1
12 mitral valve prolapse 2 12.9
13 mitral valve prolapse 3 12.8
14 chronic orthostatic intolerance 12.6
15 mitral valve prolapse, familial, autosomal dominant 12.4
16 hypogonadism-mitral valve prolapse-intellectual disability syndrome 12.4
17 brachydactyly-mesomelia-intellectual disability-heart defects syndrome 12.2
18 osteogenesis imperfecta, type v 12.1
19 osteogenesis imperfecta, type iv 12.1
20 osteogenesis imperfecta, type ii 12.0
21 osteogenesis imperfecta, type viii 12.0
22 osteogenesis imperfecta, type iii 11.9
23 osteogenesis imperfecta, type xiii 11.9
24 osteogenesis imperfecta, type xiv 11.9
25 osteogenesis imperfecta, type xv 11.9
26 osteogenesis imperfecta, type i 11.9
27 osteogenesis imperfecta, type vii 11.9
28 osteogenesis imperfecta, type xi 11.9
29 osteogenesis imperfecta, type x 11.8
30 osteogenesis imperfecta, type vi 11.8
31 cantalamessa baldini ambrosi syndrome 11.8
32 osteogenesis imperfecta, type xii 11.8
33 spastic ataxia, charlevoix-saguenay type 11.6
34 mass syndrome 11.6
35 ehlers-danlos syndrome, classic-like, 2 11.5
36 mitral valve prolapse 1 11.5
37 dentinogenesis imperfecta 11.4
38 arthrogryposis, distal, type 9 11.4
39 polycystic kidney disease 1 with or without polycystic liver disease 11.4
40 ehlers-danlos syndrome, cardiac valvular type 11.4
41 frank-ter haar syndrome 11.4
42 progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal recessive 1 11.4
43 cardiac valvular dysplasia, x-linked 11.4
44 dental anomalies and short stature 11.4
45 heart valve disease 11.4
46 chromosome 17q11.2 deletion syndrome 11.4
47 dahlberg borer newcomer syndrome 11.4
48 microphthalmia, syndromic 2 11.4
49 osteogenesis imperfecta, type ix 11.3
50 osteogenesis imperfecta, type xvi 11.1

Graphical network of the top 20 diseases related to Orthostatic Intolerance:



Diseases related to Orthostatic Intolerance
Sources

Symptoms & Phenotypes for Orthostatic Intolerance

About this section

Human phenotypes related to Orthostatic Intolerance:

33
# Description HPO Frequency HPO Source Accession
1 orthostatic tachycardia 33 HP:0012173

Clinical features from OMIM:

604715

UMLS symptoms related to Orthostatic Intolerance:


angina pectoris, edema, chest pain

MGI Mouse Phenotypes related to Orthostatic Intolerance:

47 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.33 ADRA2A ADRA2B ADRA2C ADRB1 ADRB2 AGTR1
2 behavior/neurological MP:0005386 10.29 ACHE ADRA2A ADRA2B ADRA2C ADRB2 AGTR1
3 homeostasis/metabolism MP:0005376 10.27 ACHE ADRA2A ADRA2B ADRA2C ADRB1 ADRB2
4 growth/size/body region MP:0005378 10.25 ACHE ADRA2B ADRB1 ADRB2 AGTR1 ECE1
5 mortality/aging MP:0010768 10.2 ACHE ADRA2A ADRA2B ADRA2C ADRB1 AGTR1
6 adipose tissue MP:0005375 10.1 ACHE ADRB1 ADRB2 AGTR1 FBN1 NOS2
7 hematopoietic system MP:0005397 10.1 ACHE ADRA2B ADRB2 AGTR1 ECE1 FBN1
8 nervous system MP:0003631 9.97 ACHE ADRA2A ADRA2C ADRB2 AGTR1 ECE1
9 muscle MP:0005369 9.96 ACHE ADRA2B ADRB1 ADRB2 ECE1 EDN1
10 renal/urinary system MP:0005367 9.5 ADRA2B AGTR1 EDN1 FBN1 NOS2 NOS3
11 skeleton MP:0005390 9.28 ADRB1 ADRB2 ECE1 EDN1 FBN1 FLNA
Sources

Drugs & Therapeutics for Orthostatic Intolerance

About this section

PubMedHealth treatment related to Orthostatic Intolerance: 64

Most people who have mitral valve prolapse (MVP) don't need treatment because they don't have symptoms and complications.Even people who do have symptoms may not need treatment. The presence of symptoms doesn't always mean that the backflow of blood through the valve is significant.People who have MVP and troublesome mitral valve backflow usually need treatment. MVP is treated with medicines, surgery, or both.The goals of treating MVP include:Preventing infective endocarditis (IE), arrhythmias, and other complicationsRelieving symptomsCorrecting the underlying mitral valve problem, if necessary

Drugs for Orthostatic Intolerance (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 298)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Midodrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 133163-28-7, 42794-76-3 4195
2
Droxidopa Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 23651-95-8 443940
3
Norepinephrine Approved Phase 4,Phase 2,Phase 1 51-41-2 439260
4
Metoprolol Approved, Investigational Phase 4,Phase 2,Not Applicable 37350-58-6, 51384-51-1 4171
5
Propranolol Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable,Early Phase 1 525-66-6 4946
6
Acetaminophen Approved Phase 4 103-90-2 1983
7
Morphine Approved, Investigational Phase 4 57-27-2 5288826
8
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
9
Bisoprolol Approved Phase 4 66722-44-9 2405
10
Fludrocortisone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 127-31-1 31378
11 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
12 Adrenergic Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
13 Vasoconstrictor Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
14 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
15 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
16 Sympathomimetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
17 Adrenergic alpha-Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
18 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
19 Antihypertensive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
20 Anti-Arrhythmia Agents Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
21 Adrenergic beta-Antagonists Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
22 Adrenergic Antagonists Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
24 Atomoxetine Hydrochloride Phase 4,Phase 3,Phase 2,Phase 1
25 Antiparkinson Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
26 Adrenergic beta-1 Receptor Antagonists Phase 4,Phase 2,Phase 1,Not Applicable
27 Sympatholytics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Vasodilator Agents Phase 4,Phase 1,Phase 2,Not Applicable,Early Phase 1
29 Cola Phase 4
30 Central Nervous System Depressants Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
31 Analgesics, Opioid Phase 4
32 Antipyretics Phase 4
33 Anesthetics Phase 4,Phase 1,Not Applicable
34 Anesthetics, Local Phase 4,Phase 1,Not Applicable
35 Narcotics Phase 4
36 Analgesics, Non-Narcotic Phase 4,Phase 1,Phase 2
37 Analgesics Phase 4,Phase 1,Phase 2
38 Cholinergic Agents Phase 4,Phase 1,Phase 2,Early Phase 1,Not Applicable
39 Pyridostigmine Bromide Phase 4,Phase 2,Phase 1,Early Phase 1,Not Applicable 101-26-8
40 Cholinesterase Inhibitors Phase 4,Phase 2,Phase 1,Early Phase 1,Not Applicable
41 Anticonvulsants Phase 4,Phase 1,Phase 2
42 Bromides Phase 4,Phase 2,Phase 1,Early Phase 1,Not Applicable
43 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
44
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3,Not Applicable 2921-57-5
45
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3,Not Applicable 83-43-2 6741
46
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3,Not Applicable 302-25-0
47
Prednisolone Approved, Vet_approved Phase 2, Phase 3,Not Applicable 50-24-8 5755
48
Carbidopa Approved Phase 2, Phase 3,Phase 3,Phase 1 28860-95-9 34359
49
Dopamine Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 62-31-7, 51-61-6 681
50
Levodopa Approved Phase 3,Phase 1,Early Phase 1 59-92-7 6047

Interventional clinical trials:

(show top 50) (show all 246)
# Name Status NCT ID Phase Drugs
1 Closed Loop Stimulation for Neuromediated Syncope (SPAIN Study) Unknown status NCT01621464 Phase 4
2 Assessment of Midodrine in the Prevention of Vasovagal Syncope: The Prevention of Syncope Trial IV Unknown status NCT01456481 Phase 4 midodrine hydrochloride;matching placebo
3 Radical Prostatectomy and Perioperative Fluid Therapy Completed NCT00771966 Phase 4
4 Propranolol to Treat Fainting Due to Sympathoadrenal Imbalance Completed NCT00060866 Phase 4 Propranolol
5 TQL-block for Laparoscopic Hemicolectomy Recruiting NCT03570541 Phase 4 Ropivacaine;Acetaminophen;Morphine;Saline
6 Efficacy and Safety of Midodrine and Atomoxetine for Neurogenic OH Recruiting NCT03350659 Phase 4 Midodrine;Atomoxetine
7 Dawn Simulation and Postural Hypotension Recruiting NCT02632318 Phase 4
8 Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension Recruiting NCT02586623 Phase 4 Droxidopa capsules;Placebo capsules
9 Treatment and Prognosis of Neurogenic Orthostatic Hypotension : A Prospective Randomized Study Completed NCT02308124 Phase 4 Midodrine;Pyridostigmine Bromide;Midodrine + pyridostigmine
10 Tilt-Table Study of the Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension Completed NCT01518946 Phase 4 Midodrine HCl;Placebo
11 Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension Completed NCT01515865 Phase 4 Midodrine HCl;Placebo
12 Study to Assess the Benefit of Midodrine in the Treatment of Patients With Neurogenic Orthostatic Hypotension Completed NCT00555880 Phase 4 Midodrine hydrochloride;Placebo
13 A Study for Patients With Neurogenic Orthostatic Hypotension Completed NCT00046475 Phase 4 Midodrine Hydrochloride
14 A Phase IV Study in Subjects With Neurogenic Orthostatic Hypotension Terminated NCT00046163 Phase 4 midodrine hydrochloride (ProAmatine®)
15 Dose Response to the Norepinephrine Precursor Droxidopa in Hypotensive Individuals With Spinal Cord Injury Recruiting NCT03602014 Phase 4 Northera
16 Brain Perfusion & Oxygenation in Parkinson's Disease With NOH Recruiting NCT03229174 Phase 4 Droxidopa;Placebo
17 Effect of Medical Treatment and Prognosis of Postural Orthostatic Tachycardia Syndrome (POTS) Completed NCT02171988 Phase 4 Propranolol;Bisoprolol;Propranolol+pyridostigmine;Bisoprolol+pyridostgmine
18 Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects Recruiting NCT02123056 Phase 4 Metoprolol;Matching Placebo
19 Clinical Trial for the Prevention of Vasovagal Syncope Completed NCT00118482 Phase 4 fludrocortisone acetate
20 Efficacy of L-threo DOPS on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With MSA Unknown status NCT02071459 Phase 2, Phase 3 L-Threo DOPS;placebo
21 Effect of Methylprednisolone on Orthostatic Intolerance and Heart Rate Variability in Hip-arthroplasty Patients Completed NCT02445898 Phase 2, Phase 3 Methylprednisolone;Isotonic Sodium Chloride
22 Efficacy of Midodrine for the Prevention of Orthostatic Hypotension During Early Mobilization After Fast-track Hip Arthroplasty Completed NCT01707953 Phase 3 Midodrine;Placebo
23 A Study to Systematically Assess the Efficacy and Safety of Intravenous Albumin Infusions in Severe POTS Not yet recruiting NCT03365414 Phase 3 Normal Saline 0.9% Infusion Solution Bag
24 Peripheral Dopamine in Postural Tachycardia Syndrome Active, not recruiting NCT00685919 Phase 2, Phase 3 Carbidopa;Placebo
25 Treatment of Orthostatic Hypotension Enrolling by invitation NCT00581477 Phase 3 droxidopa;placebo;alpha-methyldopa;carbidopa;metyrosine;levodopa;atomoxetine;metoclopramide
26 Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver Transplant Recruiting NCT03862807 Phase 3 Patisiran
27 Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) (Droxi-304) Completed NCT01132326 Phase 3 Droxidopa
28 A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa Completed NCT00782340 Phase 3 Placebo;Droxidopa
29 Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) Completed NCT00633880 Phase 3 Placebo;Droxidopa
30 APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis Completed NCT01960348 Phase 3 patisiran (ALN-TTR02);Sterile Normal Saline (0.9% NaCl)
31 Clinical Effect Durability of TD-9855 for Treating snOH in Subjects With Primary Autonomic Failure Recruiting NCT03829657 Phase 3 TD-9855;Placebo
32 Clinical Effect of TD-9855 for Treating snOH in Subjects With Primary Autonomic Failure Recruiting NCT03750552 Phase 3 TD-9855;Placebo
33 Phase 3 Study to Evaluate the Efficacy and Safety of Droxidopa on Orthostatic Hypotension Treatment in Hemodialysis Patients Terminated NCT01612078 Phase 3 Droxidopa;Placebo
34 Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome Recruiting NCT03182725 Phase 3 Ivabradine;Placebo
35 Treatment of Post-SCI Hypotension Recruiting NCT02919917 Phase 2, Phase 3 Midodrine Hydrochloride;Midodrine Hydrochloride
36 Stop Vasodepressor Drugs in Reflex Syncope Completed NCT02137278 Phase 3 Vasoactive drug therapies
37 Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) Completed NCT00738062 Phase 3 Droxidopa;Placebo
38 A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy Terminated NCT01927055 Phase 3 Droxidopa;Placebo
39 A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease Completed NCT01176240 Phase 3 Droxidopa
40 Circulating Transforming Growth Factor Beta (TGF-β) in Individuals With Marfan Syndrome Withdrawn NCT01361087 Phase 3
41 Second Study on Cardio-neuromodulation in Humans Unknown status NCT02954666 Phase 2
42 A Proof of Principal Study of Atomoxetine for the Prevention of Vasovagal Syncope Unknown status NCT02874937 Phase 2 Atomoxetine;Matching Placebo
43 The Effect of Ivabradine on Patients With Postural Tachycardia Syndrome Unknown status NCT01761825 Phase 2 ivabradine
44 Cardiovascular Effects of Selective I(f)-Channel Blockade Unknown status NCT00865917 Phase 2 beta-blocker (Metoprolol);I(f)-blocker (ivabradine);Placebo
45 Fipamezole in Neurogenic Orthostatic Hypotension Unknown status NCT00758849 Phase 2 Placebo;Fipamezole
46 Safety and Efficacy Study of a New Device for Making Neochordae in Mitral Valve Repair Unknown status NCT01811537 Phase 1, Phase 2
47 Treatment of Orthostatic Intolerance Active, not recruiting NCT00262470 Phase 1, Phase 2 Acetazolamide;Atomoxetine;Clonidine;Entacapone;Entacapone & Propranolol;Atomoxetine & Propranolol;Indomethacin;Mecamylamine;Isosorbide Dinitrate;Midodrine;Modafinil;Octreotide;Propranolol;Modafinil & Propranolol;Sertraline;memantine
48 Sex Hormones and Orthostatic Tolerance Completed NCT01153581 Phase 2 Ganirelix acetate;17β-Oestradiol;Progesterone
49 Hemodynamic Response of Neuropathic And Non-Neuropathic POTS Patients To Adrenoreceptor Agonist And Antagonist Terminated NCT03070730 Phase 1, Phase 2 Droxidopa;Atenolol;Placebos
50 Northera Improves Postural Tachycardia Syndrome (POTS) and Postural Vasovagal Syncope (VVS) Recruiting NCT02558972 Phase 2 Northera (Droxidopa);Placebo;Northera (Droxidopa);Placebo

Search NIH Clinical Center for Orthostatic Intolerance

Cochrane evidence based reviews: neurocirculatory asthenia

Sources

Genetic Tests for Orthostatic Intolerance

About this section

Genetic tests related to Orthostatic Intolerance:

# Genetic test Affiliating Genes
1 Orthostatic Intolerance 30 SLC6A2
2 Mitral Valve Prolapse 30
Sources

Anatomical Context for Orthostatic Intolerance

About this section

MalaCards organs/tissues related to Orthostatic Intolerance:

42
Heart, Brain, Testes, Lung, Spinal Cord, Liver, Thyroid
Sources

Publications for Orthostatic Intolerance

About this section

Articles related to Orthostatic Intolerance:

(show top 50) (show all 2115)
# Title Authors Year
1
Atrial Fibrillation and Mitral Valve Prolapse: Time to Intervene? ( 30678756 )
2019
2
Prevalence and clinical phenotype of concomitant long QT syndrome and arrhythmogenic bileaflet mitral valve prolapse. ( 30219255 )
2019
3
Utility of Diagnostic Studies for Upper Gastrointestinal Symptoms in Children with Orthostatic Intolerance. ( 30529135 )
2019
4
Orthostatic intolerance following hip arthroplasty: incidence, risk factors and effect on length of stay: A prospective cohort study. ( 30540643 )
2019
5
The Orthostatic Discriminant and Severity Scale (ODSS): an assessment of orthostatic intolerance. ( 30604164 )
2019
6
Cerebral Perfusion Monitoring Using Near-Infrared Spectroscopy During Head-Up Tilt Table Test in Patients With Orthostatic Intolerance. ( 30837856 )
2019
7
Associations Between Autonomic and Orthostatic Self-report and Physician Ratings of Orthostatic Intolerance in Youth. ( 30876666 )
2019
8
Trends in mitral valve prolapse: a tertiary care center experience in Jeddah, Saudi Arabia. ( 30666148 )
2019
9
Management and outcomes in MVP with ventricular arrhythmias (VAs) undergoing ablation and/or implantation of ICDs. ( 30680747 )
2019
10
Predictive Factors for Progression of Mitral Regurgitation in Asymptomatic Patients With Mitral Valve Prolapse. ( 30711245 )
2019
11
Left ventricular mechanical dispersion predicts arrhythmic risk in mitral valve prolapse. ( 30755467 )
2019
12
Arrhythmic Mitral Annulus Disjunction and Mitral Valve Prolapse: Components of the Same Clinical Spectrum? ( 30765046 )
2019
13
Reply: Arrhythmic Mitral Annulus Disjunction and Mitral Valve Prolapse: Components of the Same Clinical Spectrum? ( 30765047 )
2019
14
Papillary Muscle Ventricular Arrhythmias in Patients with Arrhythmic Mitral Valve Prolapse: Electrophysiologic Substrate and Catheter Ablation Outcomes. ( 30843306 )
2019
15
From mitral valve prolapse to catheter ablation. ( 30879029 )
2019
16
Unusual combination of mitral valve prolapse, bicuspid aortic valve, and ventricular septal defect restricted by the tricuspid septal leaflet. ( 29339711 )
2018
17
Intravenous saline administration in patients with severe acquired brain injury and orthostatic intolerance for tilt-table mobilization. ( 29190150 )
2018
18
Weighting of orthostatic intolerance time measurements with standing difficulty score stratifies ME/CFS symptom severity and analyte detection. ( 29650052 )
2018
19
Orthostatic tachycardia with different onset time in patients with orthostatic intolerance. ( 29801880 )
2018
20
Intracranial compliance is associated with symptoms of orthostatic intolerance in chronic fatigue syndrome. ( 29969498 )
2018
21
Orthostatic intolerance and postural tachycardia syndrome: new insights into pathophysiology and treatment. ( 29696346 )
2018
22
The etiologic relation between disequilibrium and orthostatic intolerance in patients with myalgic encephalomyelitis (chronic fatigue syndrome). ( 29588088 )
2018
23
Emotional orienting during interoceptive threat in orthostatic intolerance: Dysautonomic contributions to psychological symptomatology in the postural tachycardia syndrome and vasovagal syncope. ( 29519640 )
2018
24
Pediatric Disorders of Orthostatic Intolerance. ( 29222399 )
2018
25
Postural tachycardia syndrome and other forms of orthostatic intolerance in Ehlers-Danlos syndrome. ( 29519641 )
2018
26
Changes in the augmentation index and postoperative orthostatic intolerance in orthopedic surgery: a prospective cohort study. ( 29790120 )
2018
27
Prefrontal hemodynamic changes measured using near-infrared spectroscopy during the Valsalva maneuver in patients with orthostatic intolerance. ( 29392157 )
2018
28
Mitral valve prolapse and aortic root dilation in adults with hypermobile Ehlers-Danlos syndrome and related disorders. ( 30063091 )
2018
29
Infective Endocarditis in Patients With Bicuspid Aortic Valve or Mitral Valve Prolapse. ( 29903346 )
2018
30
Orthostatic intolerance in enhanced recovery laparoscopic colorectal resection. ( 30094811 )
2018
31
Chronic nausea and orthostatic intolerance: Diagnostic utility of orthostatic challenge duration, Nausea Profile Questionnaire, and neurohumoral measures. ( 30101470 )
2018
32
Assessment of cerebral autoregulation using continuous-wave near-infrared spectroscopy during squat-stand maneuvers in subjects with symptoms of orthostatic intolerance. ( 30185974 )
2018
33
Hypocapnic cerebral hypoperfusion: A biomarker of orthostatic intolerance. ( 30256820 )
2018
34
Orthostatic Intolerance and Coagulation Abnormalities: An Update. ( 30315398 )
2018
35
Cardiovascular variability in young male and female subjects in health and orthostatic intolerance. ( 30441020 )
2018
36
The Prevalence of Mitral Valve Prolapse in Panic Disorder: A Meta-Analysis. ( 30448200 )
2018
37
A Case of Single Atrium, Mitral Valve Prolapse Spontaneously - Closed Inlet VSD with Polydactyly. ( 30487512 )
2018
38
Association between mitral valve prolapse and sudden sensorineural hearing loss: A case-control population-based study. ( 30286192 )
2018
39
An unusual case of double-chambered left ventricle : A case of double-chambered left ventricle communicated with right ventricle through a ventricular septal defect presented during only in diastole and a concomitant mitral valve prolapse. ( 30097833 )
2018
40
Correction to: Hiatal hernia, mitral valve prolapse and defecatory disorders: An underlying rectal prolapse? ( 30324409 )
2018
41
Corneal Sublayers Thickness in Patients With Mitral Valve Prolapse. ( 27541972 )
2018
42
Imaging characteristics of papillary muscle site of origin of ventricular arrhythmias in patients with mitral valve prolapse. ( 29059484 )
2018
43
Aortic elasticity and carotid intima-media thickness in children with mitral valve prolapse. ( 29110750 )
2018
44
Deleterious variants in DCHS1 are prevalent in sporadic cases of mitral valve prolapse. ( 29224215 )
2018
45
Genetics of syndromic and non-syndromic mitral valve prolapse. ( 29352010 )
2018
46
Assesment of Rhythm Disorders in Classical and Nonclassical Mitral Valve Prolapse. ( 29416210 )
2018
47
Transthoracic echocardiography in patients undergoing mitral valve repair: comparison of new transthoracic 3D techniques to 2D transoesophageal echocardiography in the localization of mitral valve prolapse. ( 29484557 )
2018
48
Papillary muscle ventricular arrhythmias among patients with mitral valve prolapse. ( 29485223 )
2018
49
Genomic analysis in patients with myxomatous mitral valve prolapse: current state of knowledge. ( 29486707 )
2018
50
Grading of mitral regurgitation in mitral valve prolapse using the average pixel intensity method. ( 29544951 )
2018
Sources

Variations for Orthostatic Intolerance

About this section

UniProtKB/Swiss-Prot genetic disease variations for Orthostatic Intolerance:

76
# Symbol AA change Variation ID SNP ID
1 SLC6A2 p.Ala457Pro VAR_010022 rs121918126

ClinVar genetic disease variations for Orthostatic Intolerance:

6 (show top 50) (show all 143)
# Gene Variation Type Significance SNP ID Assembly Location
1 SLC39A13 NM_152264.4(SLC39A13): c.398C> T (p.Thr133Met) single nucleotide variant Conflicting interpretations of pathogenicity rs140574574 GRCh37 Chromosome 11, 47433573: 47433573
2 SLC39A13 NM_152264.4(SLC39A13): c.398C> T (p.Thr133Met) single nucleotide variant Conflicting interpretations of pathogenicity rs140574574 GRCh38 Chromosome 11, 47412022: 47412022
3 SLC6A2 NM_001172504.1(SLC6A2): c.1369G> C (p.Ala457Pro) single nucleotide variant Pathogenic rs121918126 GRCh37 Chromosome 16, 55731917: 55731917
4 SLC6A2 NM_001172504.1(SLC6A2): c.1369G> C (p.Ala457Pro) single nucleotide variant Pathogenic rs121918126 GRCh38 Chromosome 16, 55698005: 55698005
5 PACS1 NM_018026.3(PACS1): c.607C> T (p.Arg203Trp) single nucleotide variant Pathogenic rs398123009 GRCh37 Chromosome 11, 65978677: 65978677
6 PACS1 NM_018026.3(PACS1): c.607C> T (p.Arg203Trp) single nucleotide variant Pathogenic rs398123009 GRCh38 Chromosome 11, 66211206: 66211206
7 BMPR2 NM_001204.6(BMPR2): c.2948G> A (p.Arg983Gln) single nucleotide variant Likely benign rs148099152 GRCh38 Chromosome 2, 202559777: 202559777
8 BMPR2 NM_001204.6(BMPR2): c.2948G> A (p.Arg983Gln) single nucleotide variant Likely benign rs148099152 GRCh37 Chromosome 2, 203424500: 203424500
9 SLC6A2 NM_001043.3(SLC6A2): c.-182C> T single nucleotide variant Likely benign rs2242446 GRCh38 Chromosome 16, 55656513: 55656513
10 SLC6A2 NM_001043.3(SLC6A2): c.-182C> T single nucleotide variant Likely benign rs2242446 GRCh37 Chromosome 16, 55690425: 55690425
11 SLC6A2 NM_001043.3(SLC6A2): c.21C> A (p.Asn7Lys) single nucleotide variant Uncertain significance rs11568323 GRCh38 Chromosome 16, 55656715: 55656715
12 SLC6A2 NM_001043.3(SLC6A2): c.21C> A (p.Asn7Lys) single nucleotide variant Uncertain significance rs11568323 GRCh37 Chromosome 16, 55690627: 55690627
13 SLC6A2 NM_001043.3(SLC6A2): c.48G> C (p.Gly16=) single nucleotide variant Uncertain significance rs551459843 GRCh38 Chromosome 16, 55656742: 55656742
14 SLC6A2 NM_001043.3(SLC6A2): c.48G> C (p.Gly16=) single nucleotide variant Uncertain significance rs551459843 GRCh37 Chromosome 16, 55690654: 55690654
15 SLC6A2 NM_001043.3(SLC6A2): c.52G> C (p.Asp18His) single nucleotide variant Uncertain significance rs886052131 GRCh38 Chromosome 16, 55656746: 55656746
16 SLC6A2 NM_001043.3(SLC6A2): c.52G> C (p.Asp18His) single nucleotide variant Uncertain significance rs886052131 GRCh37 Chromosome 16, 55690658: 55690658
17 SLC6A2 NM_001043.3(SLC6A2): c.275-15C> T single nucleotide variant Uncertain significance rs886052132 GRCh38 Chromosome 16, 55669550: 55669550
18 SLC6A2 NM_001043.3(SLC6A2): c.275-15C> T single nucleotide variant Uncertain significance rs886052132 GRCh37 Chromosome 16, 55703462: 55703462
19 SLC6A2 NM_001043.3(SLC6A2): c.866A> G (p.Asn289Ser) single nucleotide variant Uncertain significance rs77951841 GRCh37 Chromosome 16, 55725912: 55725912
20 SLC6A2 NM_001043.3(SLC6A2): c.866A> G (p.Asn289Ser) single nucleotide variant Uncertain significance rs77951841 GRCh38 Chromosome 16, 55692000: 55692000
21 SLC6A2 NM_001043.3(SLC6A2): c.918+11A> G single nucleotide variant Likely benign rs5564 GRCh37 Chromosome 16, 55725975: 55725975
22 SLC6A2 NM_001043.3(SLC6A2): c.918+11A> G single nucleotide variant Likely benign rs5564 GRCh38 Chromosome 16, 55692063: 55692063
23 SLC6A2 NM_001043.3(SLC6A2): c.1401C> T (p.Tyr467=) single nucleotide variant Uncertain significance rs138435822 GRCh37 Chromosome 16, 55732392: 55732392
24 SLC6A2 NM_001043.3(SLC6A2): c.1401C> T (p.Tyr467=) single nucleotide variant Uncertain significance rs138435822 GRCh38 Chromosome 16, 55698480: 55698480
25 SLC6A2 NM_001043.3(SLC6A2): c.1465G> A (p.Ala489Thr) single nucleotide variant Uncertain significance rs762006683 GRCh37 Chromosome 16, 55732456: 55732456
26 SLC6A2 NM_001043.3(SLC6A2): c.1465G> A (p.Ala489Thr) single nucleotide variant Uncertain significance rs762006683 GRCh38 Chromosome 16, 55698544: 55698544
27 SLC6A2 NM_001043.3(SLC6A2): c.*371G> A single nucleotide variant Likely benign rs115138076 GRCh38 Chromosome 16, 55702717: 55702717
28 SLC6A2 NM_001043.3(SLC6A2): c.*371G> A single nucleotide variant Likely benign rs115138076 GRCh37 Chromosome 16, 55736629: 55736629
29 SLC6A2 NM_001043.3(SLC6A2): c.*396_*397dupCC duplication Uncertain significance rs35571499 GRCh38 Chromosome 16, 55702742: 55702743
30 SLC6A2 NM_001043.3(SLC6A2): c.*396_*397dupCC duplication Uncertain significance rs35571499 GRCh37 Chromosome 16, 55736654: 55736655
31 SLC6A2 NM_001043.3(SLC6A2): c.*414_*415insC insertion Uncertain significance rs886052137 GRCh38 Chromosome 16, 55702760: 55702761
32 SLC6A2 NM_001043.3(SLC6A2): c.*414_*415insC insertion Uncertain significance rs886052137 GRCh37 Chromosome 16, 55736672: 55736673
33 SLC6A2 NM_001043.3(SLC6A2): c.*416delC deletion Uncertain significance rs113163898 GRCh38 Chromosome 16, 55702762: 55702762
34 SLC6A2 NM_001043.3(SLC6A2): c.*416delC deletion Uncertain significance rs113163898 GRCh37 Chromosome 16, 55736674: 55736674
35 SLC6A2 NM_001043.3(SLC6A2): c.*417T> A single nucleotide variant Likely benign rs40615 GRCh38 Chromosome 16, 55702763: 55702763
36 SLC6A2 NM_001043.3(SLC6A2): c.*417T> A single nucleotide variant Likely benign rs40615 GRCh37 Chromosome 16, 55736675: 55736675
37 SLC6A2 NM_001043.3(SLC6A2): c.*606T> C single nucleotide variant Likely benign rs111663130 GRCh38 Chromosome 16, 55702952: 55702952
38 SLC6A2 NM_001043.3(SLC6A2): c.*606T> C single nucleotide variant Likely benign rs111663130 GRCh37 Chromosome 16, 55736864: 55736864
39 SLC6A2 NM_001043.3(SLC6A2): c.*919_*921delACC deletion Uncertain significance rs540636734 GRCh38 Chromosome 16, 55703265: 55703267
40 SLC6A2 NM_001043.3(SLC6A2): c.*919_*921delACC deletion Uncertain significance rs540636734 GRCh37 Chromosome 16, 55737177: 55737179
41 SLC6A2 NM_001043.3(SLC6A2): c.*1017G> A single nucleotide variant Uncertain significance rs886052141 GRCh38 Chromosome 16, 55703363: 55703363
42 SLC6A2 NM_001043.3(SLC6A2): c.*1017G> A single nucleotide variant Uncertain significance rs886052141 GRCh37 Chromosome 16, 55737275: 55737275
43 SLC6A2 NM_001043.3(SLC6A2): c.*1175A> G single nucleotide variant Uncertain significance rs886052142 GRCh38 Chromosome 16, 55703521: 55703521
44 SLC6A2 NM_001043.3(SLC6A2): c.*1175A> G single nucleotide variant Uncertain significance rs886052142 GRCh37 Chromosome 16, 55737433: 55737433
45 SLC6A2 NM_001043.3(SLC6A2): c.407-12G> A single nucleotide variant Likely benign rs11568343 GRCh38 Chromosome 16, 55671926: 55671926
46 SLC6A2 NM_001043.3(SLC6A2): c.407-12G> A single nucleotide variant Likely benign rs11568343 GRCh37 Chromosome 16, 55705838: 55705838
47 SLC6A2 NM_001043.3(SLC6A2): c.848C> G (p.Thr283Arg) single nucleotide variant Likely benign rs45564432 GRCh37 Chromosome 16, 55725894: 55725894
48 SLC6A2 NM_001043.3(SLC6A2): c.848C> G (p.Thr283Arg) single nucleotide variant Likely benign rs45564432 GRCh38 Chromosome 16, 55691982: 55691982
49 SLC6A2 NM_001043.3(SLC6A2): c.1389+9G> A single nucleotide variant Likely benign rs998424 GRCh37 Chromosome 16, 55731946: 55731946
50 SLC6A2 NM_001043.3(SLC6A2): c.1389+9G> A single nucleotide variant Likely benign rs998424 GRCh38 Chromosome 16, 55698034: 55698034
Sources

Expression for Orthostatic Intolerance

About this section
Search GEO for disease gene expression data for Orthostatic Intolerance.
Sources

Pathways for Orthostatic Intolerance

About this section

Pathways related to Orthostatic Intolerance according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Peptide ligand-binding receptors 67
Show member pathways
 13.41 ADRA2A ADRA2B ADRA2C ADRB1 ADRB2 AGTR1
2
NFAT and Cardiac Hypertrophy 65
Show member pathways
 12.7 ADRA2A ADRA2B ADRB1 ADRB2 EDN1
3
Vascular smooth muscle contraction 38
Show member pathways
 12.46 ADRA2A ADRA2B ADRA2C ADRB1 ADRB2 AGTR1
4
ADP signalling through P2Y purinoceptor 12 67
Show member pathways
 12.35 ADRA2A ADRA2B ADRA2C ADRB2 POMC
5
Calcium signaling pathway 38
12.08 ADRB1 ADRB2 AGTR1 NOS2 NOS3
6
AMPK Enzyme Complex Pathway 65
Show member pathways
 12 ADRA2A ADRA2B ADRA2C NOS2 NOS3
7
HIF-1 signaling pathway 38
11.77 EDN1 NOS2 NOS3
8
AGE-RAGE signaling pathway in diabetic complications 38
11.76 AGTR1 EDN1 NOS3
9
Monoamine GPCRs 1
Show member pathways
 11.76 ADRA2A ADRA2B ADRA2C ADRB1 ADRB2
10
Integrin alphaIIb beta3 signaling 67
Show member pathways
 11.74 ADRA2A ADRA2B ADRA2C
11
Corticotropin-releasing hormone signaling pathway 1
11.7 ECE1 NOS3 POMC
12
Renin secretion 38
11.53 ADRB1 ADRB2 AGTR1
13
Antiarrhythmic Pathway, Pharmacodynamics 62
11.42 ADRA2A ADRB1 ADRB2
14
G-protein signaling_Cross-talk between Ras-family GTPases 23
11.22 ADRA2A ADRA2B ADRB1 ADRB2
15
Melatonin metabolism and effects 1
11.02 ACHE ADRB1 ECE1 EDN1
16
Hypothesized Pathways in Pathogenesis of Cardiovascular Disease 1
11.01 AGTR1 FBN1 FLNA
17
Endothelin Pathways 1
10.79 ADRB1 ECE1 EDN1 NOS3
18
NO-dependent CFTR activation (normal and CF) 23
10.66 NOS2 NOS3
19
Sympathetic Nerve Pathway (Neuroeffector Junction) 62
10.46 ADRA2A ADRA2B ADRA2C ADRB1 ADRB2 SLC6A2
20
Effects of Nitric Oxide 1
10.43 NOS2 NOS3
Sources

GO Terms for Orthostatic Intolerance

About this section

Cellular components related to Orthostatic Intolerance according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.77 ACHE ADRA2A ADRA2B ADRA2C ADRB1 ADRB2
2 integral component of plasma membrane GO:0005887 9.7 ADRA2A ADRA2B ADRA2C ADRB1 ADRB2 AGTR1
3 Weibel-Palade body GO:0033093 8.62 ECE1 EDN1

Biological processes related to Orthostatic Intolerance according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 9.89 ADRA2B ADRA2C EDN1 POMC
2 positive regulation of MAPK cascade GO:0043410 9.85 ADRA2A ADRA2B ADRA2C ADRB2
3 adenylate cyclase-activating G protein-coupled receptor signaling pathway GO:0007189 9.81 ADRA2A ADRB1 ADRB2
4 platelet activation GO:0030168 9.81 ADRA2A ADRA2B ADRA2C FLNA
5 positive regulation of cold-induced thermogenesis GO:0120162 9.8 ACHE ADRB1 ADRB2
6 regulation of insulin secretion GO:0050796 9.76 ADRA2A ADRA2C NOS2
7 regulation of blood pressure GO:0008217 9.74 EDN1 NOS3 POMC
8 activation of protein kinase B activity GO:0032148 9.7 ADRA2A ADRA2B ADRA2C
9 regulation of sodium ion transport GO:0002028 9.65 ADRB2 NOS3
10 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.65 ADRA2A ADRA2B ADRA2C ADRB1 ADRB2
11 nitric oxide mediated signal transduction GO:0007263 9.64 NOS2 NOS3
12 regulation of blood vessel size GO:0050880 9.64 EDN1 NOS3
13 negative regulation of norepinephrine secretion GO:0010700 9.63 ADRA2A ADRA2B ADRA2C
14 negative regulation of calcium ion transport GO:0051926 9.62 ADRA2A NOS3
15 regulation of blood vessel diameter GO:0097746 9.62 ADRB2 AGTR1
16 regulation of smooth muscle contraction GO:0006940 9.62 ADRA2A ADRA2B ADRA2C ADRB2
17 nitric oxide biosynthetic process GO:0006809 9.61 NOS2 NOS3
18 negative regulation of multicellular organism growth GO:0040015 9.61 ADRB1 ADRB2
19 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.61 ECE1 EDN1 NOS3
20 positive regulation of guanylate cyclase activity GO:0031284 9.6 NOS2 NOS3
21 diet induced thermogenesis GO:0002024 9.58 ADRB1 ADRB2
22 negative regulation of epinephrine secretion GO:0032811 9.58 ADRA2A ADRA2B ADRA2C
23 arginine catabolic process GO:0006527 9.56 NOS2 NOS3
24 norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure GO:0002025 9.54 ADRB1 ADRB2
25 receptor transactivation GO:0035624 9.54 ADRA2A ADRA2B ADRA2C
26 heat generation GO:0031649 9.48 ADRB1 ADRB2
27 adrenergic receptor signaling pathway GO:0071875 9.46 ADRA2A ADRA2B ADRA2C ADRB2
28 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.35 ADRA2A ADRA2B ADRA2C ADRB1 ADRB2
29 regulation of vasoconstriction GO:0019229 9.1 ADRA2A ADRA2B ADRA2C AGTR1 ECE1 EDN1
30 G protein-coupled receptor signaling pathway GO:0007186 10.1 ADRA2A ADRA2B ADRA2C ADRB1 ADRB2 AGTR1

Molecular functions related to Orthostatic Intolerance according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 9.92 ACHE ADRA2A ADRA2C ADRB2 ECE1 FLNA
2 hormone activity GO:0005179 9.69 EDN1 FBN1 POMC
3 FMN binding GO:0010181 9.49 NOS2 NOS3
4 arginine binding GO:0034618 9.48 NOS2 NOS3
5 NADPH-hemoprotein reductase activity GO:0003958 9.46 NOS2 NOS3
6 alpha-2A adrenergic receptor binding GO:0031694 9.43 ADRA2C ADRB1
7 norepinephrine binding GO:0051380 9.43 ADRA2A ADRB1 ADRB2
8 tetrahydrobiopterin binding GO:0034617 9.4 NOS2 NOS3
9 nitric-oxide synthase activity GO:0004517 9.37 NOS2 NOS3
10 adrenergic receptor activity GO:0004935 9.35 ADRA2A ADRA2B ADRA2C ADRB1 ADRB2
11 alpha2-adrenergic receptor activity GO:0004938 9.33 ADRA2A ADRA2B ADRA2C
12 epinephrine binding GO:0051379 9.02 ADRA2A ADRA2B ADRA2C ADRB1 ADRB2
Sources

Sources for Orthostatic Intolerance

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....